Sponsor-Investigators

Greg Durm

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Status

Cancer Types

Lung

Locations

Fred & Pamela Buffett Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Masonic Cancer Center, University of Minnesota, Moffitt Cancer Center, Penn State Cancer Institute, Providence Cancer Institute, Rutgers Cancer Institute of New Jersey, The Ohio State University, University of Illinois Cancer Center, University of Iowa Holden Comprehensive Cancer Center, University of Virginia Cancer Center, Virginia Commonwealth University

HCRN-LUN17-321

A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Status

Closed

Cancer Types

Lung

Locations

BTCRC-LUN15-029

A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

Status

Closed

Cancer Types

Lung

Locations

BTCRC-LUN16-081

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Status

Closed

Cancer Types

Lung

Locations